ClinicalTrials.gg
CompletedNCT01202071Updated Nov 30, 2012Results posted

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

A Phase 2 interventional study of Rabeprazole sodium, 5 mg Tablets and Rabeprazole sodium, 10 mg Tablets in Healthy, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-11-30.

Sponsored by Eisai Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

The purpose of this study is to compare the pharmacodynamics/pharmacokinetics of 5 mg, 10 mg, 20 mg and 40 mg of Rabeprazole sodium (E3810) when administered repeatedly once daily for 5 days to healthy adult male Japanese participants. This was a single-center, open-label, randomized, four-treatment, four-way crossover study.

02

Conditions studied

  • Healthy

Keywords

  • Rabeprazole
  • proton pump inhibitor
  • pharmacokinetics
  • pharmacodynamics
  • healthy adult male Japanese subjects
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy adult Japanese male between the age of 20-40
  • between 18.5-25

Exclusion criteria

Exclusion Criteria:

  • abnormal physical examination, vital signs or
  • use of any prescription medication, antacid, nutritional supplement, vitamin preparation, or herb-containing drug within the previous 4 weeks
  • use of any non-prescription medication within the previous 1 week
  • history of drug or alcohol abuse
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Rabeprazole sodium Tablets, 5 mg

    Drug: Rabeprazole sodium, 5 mg Tablets

  • Experimental
    Rabeprazole sodium Tablets, 10 mg

    Drug: Rabeprazole sodium, 10 mg Tablets

  • Experimental
    Rabeprazole sodium Tablets, 20 mg

    Drug: Rabeprazole sodium, 20 mg Tablets

  • Experimental
    Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets)

    Drug: Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)

Interventions

  • Rabeprazole sodium Tablets, 5 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

    Also known as: E3810, E3810-J081-040

  • Rabeprazole sodium Tablets, 10 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

    Also known as: E3810, E3810-J081-040

  • Rabeprazole sodium Tablets, 20 mg administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water \>= 2 hours after the completion of breakfast.

    Also known as: E3810, E3810-J081-040

  • Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days. Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer. Day 2 to Day 4: participants received a single dose with 200 mL of water, \>=2 hours after the completion of breakfast.

    Also known as: E3810, E3810-J081-040

06

What researchers measure

Primary outcomes

  1. Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration

    The 24-hour intragastric pH monitoring was performed on Day 5 of administration in each study period (Period I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

    Time frame: Day 5 of administration during Period I-IV

Secondary outcomes

  1. Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax)

    Pharmacokinetic parameter: maximal drug concentration (Cmax) measured in nanograms per milliliter (ng/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

    Time frame: Day 1 and Day 5 of administration during Period I-IV

  2. Pharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])

    Pharmacokinetic parameter: Area under the plasma concentration-time curve from time 0 (administration of the drug) to time t (the last quantifiable concentration time point). AUC measured in nanogram hours per milliliter (ng\*h/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

    Time frame: Day 1 and Day 5 of administration during Period I-IV (0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24 hours post-dose)

07

Results

Posted Nov 27, 2012

Participant flow

This study was recruited at 1 center in Japan during the period of 14-Sep-2010 to 2-Dec-2010.

Participant flow — Overall Study
MilestoneGroup A: Rapeprazole 5 mg, Then 10 mg, Then 20 mg, Then 40 mgGroup B: Rapeprazole 10 mg, Then 20 mg, Then 40 mg, Then 5 mgGroup C: Rapeprazole 20 mg, Then 40 mg, Then 5 mg, Then 10 mgGroup D: Rapeprazole 40 mg, Then 5 mg, Then 10 mg, Then 20 mg
Started6666
Completed6666
Not completed0000

Outcome measures

PrimaryPercentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration

The 24-hour intragastric pH monitoring was performed on Day 5 of administration in each study period (Period I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

Time frame:
Day 5 of administration during Period I-IV
Reported as:
Mean · Percentage of Time in a 24 Hour Period
Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration
Percentage of Time in a 24 Hour PeriodRabeprazole Sodium 5 mg TabletRabeprazole Sodium 10 mg TabletRabeprazole Sodium 20 mg TabletRabeprazole Sodium 40 mg Tablet
CYP2C19 Extensive Metabolizers 'EM' (n=16)45.63 ± 19.1757.81 ± 12.9361.36 ± 9.7271.52 ± 12.20
CYP2C19 Poor Metabolizers 'PM' (n=8)62.51 ± 14.7971.83 ± 14.6475.74 ± 20.6283.08 ± 11.13
SecondaryPharmacokinetic Parameter: Maximal Drug Concentration (Cmax)

Pharmacokinetic parameter: maximal drug concentration (Cmax) measured in nanograms per milliliter (ng/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

Time frame:
Day 1 and Day 5 of administration during Period I-IV
Reported as:
Mean · ng/mL
Pharmacokinetic Parameter: Maximal Drug Concentration (Cmax)
ng/mLRabeprazole Sodium 5 mg TabletRabeprazole Sodium 10 mg TabletRabeprazole Sodium 20 mg TabletRabeprazole Sodium 40 mg Tablet
Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16)137.7 ± 55.7253.6 ± 120.2520.0 ± 267.71007.6 ± 513.1
Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16)146.0 ± 56.4382.8 ± 82.9654.1 ± 348.41018.5 ± 516.9
Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8)185.1 ± 79.0434.7 ± 98.5891.9 ± 210.81574.2 ± 596.6
Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8)251.9 ± 55.1508.5 ± 63.8821.9 ± 231.71986.5 ± 439.1
SecondaryPharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])

Pharmacokinetic parameter: Area under the plasma concentration-time curve from time 0 (administration of the drug) to time t (the last quantifiable concentration time point). AUC measured in nanogram hours per milliliter (ng\*h/mL) was calculated on Day 1 and Day 5 of administration during each Period (I-IV). Data was displayed based on the participant's CYP2C19 genotype: CYP2C19-EM are extensive metabolizers who have normal metabolizing capacity. CYP2C19-PM are poor metabolizers with a metabolizing capacity deficiency or remarkably decreased metabolizing capacity.

Time frame:
Day 1 and Day 5 of administration during Period I-IV (0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 10, 12, 24 hours post-dose)
Reported as:
Mean · ng*h/mL
Pharmacokinetic Parameter: Area Under the Plasma Concentration-Time Curve From Time 0 to Time t (AUC[0-t])
ng*h/mLRabeprazole Sodium 5 mg TabletRabeprazole Sodium 10 mg TabletRabeprazole Sodium 20 mg TabletRabeprazole Sodium 40 mg Tablet
Day 1: CYP2C19 Extensive Metabolizers 'EM' (n=16)215.5 ± 88.4429.7 ± 209.4866.9 ± 385.61807.2 ± 949.2
Day 5: CYP2C19 Extensive Metabolizers 'EM' (n=16)235.7 ± 97.1539.1 ± 199.6993.7 ± 476.91929.6 ± 884.1
Day 1: CYP2C19 Poor Metabolizers 'PM' (n=8)455.0 ± 137.71029.6 ± 293.92112.9 ± 628.84002.3 ± 1216.0
Day 5: CYP2C19 Poor Metabolizers 'PM' (n=8)584.6 ± 137.11230.4 ± 200.02330.6 ± 662.94627.9 ± 1296.0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rabeprazole Sodium 5 mg Tablet—0/24 (0%)0/24 (0%)
Rabeprazole Sodium 10 mg Tablet—0/24 (0%)0/24 (0%)
Rabeprazole Sodium 20 mg Tablet—0/24 (0%)0/24 (0%)
Rabeprazole Sodium 40 mg Tablet—0/24 (0%)0/24 (0%)

Baseline characteristics

Age Continuous
Age Continuous(years)Entire Study Population: Group A, Group B, Group C, Group D
Mean27.7 ± 4.5
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population: Group A, Group B, Group C, Group D
Female0
Male24
Baseline Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours on Day 1
Baseline Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours on Day 1(Percentage of Time in a 24 Hour Period)Entire Study Population: Group A, Group B, Group C, Group D
CYP2C19 Extensive Metabolizers 'EM'12.57 ± 7.55
CYP2C19 Poor Metabolizers 'PM'9.91 ± 8.50
08

Study locations

1 site
  • Toshima-ku, Tokyo, Japan
09

References and documents

Publications

  • Hayato S, Hasegawa S, Hojo S, Okawa H, Abe H, Sugisaki N, Munesue M, Horai Y, Ohnishi A. Dose-response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. Eur J Clin Pharmacol. 2012 May;68(5):579-88. doi: 10.1007/s00228-011-1164-7. Epub 2011 Nov 23. PubMed 22108775 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2010
First posted
Sep 15, 2010
Start
Sep 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Nov 27, 2012
Last update
Nov 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01202071
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Sep 15, 2010
Start date
Sep 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Nov 27, 2012
Last update
Nov 30, 2012

Study contacts

Masahiro Munesue
study director · Japan/Asia Clinical Research Product Creation Unit, Japan Clinical Development, Japan Clinical Development Section
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rabeprazole

Start the discussion